New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
09:02 EDTACTGAcacia reaches settlement with Mallinckrodt over Exalgo
Actavis announced that it has reached a settlement with Mallinckrodt on outstanding patent litigation related to Actavis' generic version of the 32 mg dosage strength of Mallinckrodt's Exalgo tablets. In January of 2012, Actavis and Mallinckrodt previously settled litigation involving the 8 mg, 12 mg and 16 mg dosage strengths of the product. Under terms of the settlement agreement, Mallinckrodt has granted Actavis a royalty-free license to U.S. patents relating to Exalgo to sell Actavis' 32 mg product starting on May 15, 2014. Other details of the settlement were not disclosed.
News For ACTG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
06:09 EDTACTGAcacia Research enters into settlement, patent license agreement with Elavon
Acacia Research announced that its Credit Card Fraud Control Corporation subsidiary has entered into a settlement and patent license agreement with Elavon. The agreement resolves litigation that was pending in the United States District Court for the Northern District of Texas.
March 26, 2015
06:00 EDTACTGAcacia Research enters into settlement, patent license agreement with Leica
Subscribe for More Information
March 20, 2015
09:02 EDTACTGAcacia Research management to meet with JPMorgan
Meeting to be held in Salt Lake City on March 24 hosted by JPMorgan.
March 17, 2015
06:03 EDTACTGAcacia Research subsidiary resolves litigation with Garmin International
Acacia Research announced that its American Vehicular Sciences subsidiary has entered into a settlement and patent license agreement with Garmin International and Garmin USA. The agreement resolves litigation that was pending in the U.S. District Court for the Eastern District of Texas.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use